UNITED STATES SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

		Registrant ⊠ arty other than the Registrant □	
Chec	Pi C D D	ppropriate box: reliminary Proxy Statement onfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) refinitive Proxy Statement refinitive Additional Materials oliciting Material Pursuant to § 240.14a-12	
		Biocept, Inc. (Exact name of registrant as specified in its charter)	
		(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)	
Payr	nent of	Filing Fee (Check the appropriate box)	
\boxtimes	No fe	e required.	
	Fee co	omputed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	1.	Title of each class of securities to which transaction applies:	
	2.	Aggregate number of securities to which transaction applies:	
	3.	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):	
	4.	Proposed maximum aggregate value of transaction:	
	5.	Total fee paid:	
	Fee p	ee paid previously with preliminary materials.	
		k box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting as paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its	
	6.	Amount Previously Paid:	
	7.	Form, Schedule or Registration Statement No.:	
	8.	Filing Party:	
	9.	Date Filed:	

On May 4, 2020, Biocept, Inc. (the "Company") commenced distributing to its stockholders a Notice of Annual Meeting of Stockholders and Definitive Proxy Statement (the "Notice and Proxy Statement") for its 2020 Annual Meeting of Stockholders (the "Annual Meeting"), which was held on June 5, 2020. A copy of the Notice and Proxy Statement was filed with the Securities and Exchange Commission (the "SEC") on April 29, 2020. On May 21, 2020, the Company mailed a letter to certain of its stockholders related to Proposal 3 and Proposal 4 (the "May Letter"), which proposals are described in the Notice and Proxy Statement. A copy of the May Letter was filed with the SEC on May 21, 2020. On June 5, 2020 the Annual Meeting was adjourned prior to voting on Proposal 4 to allow additional time for voting. On June 10, 2020, the Company (i) mailed a letter to certain of its stockholders (the "June Letter") and (ii) commenced disseminating an audio recording (the "Recording") to certain of its stockholders by telephone, in each case related to Proposal 4, which proposal is described in the Notice and Proxy Statement. A copy of the June Letter and the script of the Recording were filed with the SEC on June 10, 2020. As announced during the Annual Meeting, the Annual Meeting was again adjourned prior to voting on Proposal 4 to allow additional time for voting. As announced during the reconvened Annual Meeting, the Annual Meeting is to reconvene at 1:30 p.m. Pacific Time on July 31, 2020. On July 13, 2020, the Company mailed a postcard to certain of its stockholders related to Proposal 4 (the "July Postcard"), which proposal is described in the Notice and Proxy Statement. A copy of the July Postcard is set forth below.



Biocept, Inc. Stockholders: Your Vote Is Needed — Now!

The Board of Directors recommends you vote FOR the amendment to Biocept's Certificate of Incorporation to effect a reverse stock split of Biocept's common stock at a ratio in the range of 1:5 to 1:30, as further described in Biocept's Proxy Statement. The Amendment is supported by ISS and Glass Lewis.

WHY YOU SHOULD SUPPORT THE REVERSE STOCK SPLIT:

- The reverse stock split is intended to increase the per share trading price of Biocept's common stock to satisfy the \$1.00 minimum closing bid price requirement for continued listing on the Nasdaq.
- The board believes that maintaining Biocept's Nasdaq listing may provide a broader market for our common stock.
- The board believes that maintaining Biocept's Nasdaq listing may help generate interest in Biocept among other investors.

Your vote is important.

Vote Now by calling 833-782-7147 and vote FOR the reverse stock split.

Biocept
Completing the Answer
Liquid Biopsy

Please don't delay. Make the call today.